A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Inclusion Criteria for All Participants:

ECOG performance status of 0 or 1

Inclusion Criteria for Participants with Early-stage NSCLC:

Participants must have a complete resection of a histologically or cytologically confirmed Stage IIB-IIIB (T3-N2) NSCLC
PD-L1 expression TC ≥ 1% or TPS ≥ 1%
Participants must have completed adjuvant chemotherapy at least 4 weeks and up to 12 weeks prior to randomization and must be adequately recovered from chemotherapy therapy

Inclusion Criteria for Participants with Stage IV NSCLC:

Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC
Life expectancy ≥ 18 weeks in the opinion of the investigator
PD-L1 expression TC ≥ 50% or TPS ≥ 50% or TC3 or IC3
No prior systemic treatment for Stage IV non-squamous or squamous NSCLC
Participants who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last chemotherapy, radiotherapy, or chemoradiotherapy cycle.

Exclusion Criteria for All Participants:

History of malignancy within 5 years prior to initiation of study treatment, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death
Uncontrolled tumor-related pain
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
Participants known to have a sensitizing mutation in the EGFR gene or an ALK fusion oncogene
History of leptomeningeal disease
Uncontrolled or symptomatic hypercalcemia
Active or history of autoimmune disease or immune deficiency
History of idiopathic pulmonary fibrosis, organizing pneumonia), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina

Exclusion Criteria for Participants with Stage IV NSCLC:

Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases